A milestone defined by survival

On 9 March 1981, Mary Gohlke underwent combined heart–lung transplantation at Stanford Hospital. Bruce Reitz led the surgical team, working with Norman Shumway and John Wallwork. Gohlke, a 45-year-old woman from Arizona, had the condition then called primary pulmonary hypertension, which had also damaged her heart. She survived for five years after receiving the donor organs. These details are recorded in Stanford’s interview with Reitz.

The qualification “successful” matters. This was not the first attempt to transplant a human heart and lungs together. Stanford’s historical timeline identifies it as the fourth attempt worldwide. Its distinction rests on sustained survival and recovery rather than the completion of an unprecedented surgical procedure. It therefore belongs within the longer history of organ transplantation, where technical accomplishment and lasting clinical benefit did not always arrive together.

From experimental surgery to a patient

The operation brought together surgical research and a changing approach to immunosuppression. In his later recollections, Reitz described experiments in which the team first removed and replaced organs in the same animal, separating technical problems from rejection. Subsequent experiments investigated transplantation between animals and the effects of cyclosporin A. The drug offered a way to suppress rejection while allowing the airway connection to heal, a particularly important obstacle in lung transplantation. This account places the achievement within an international research network involving Stanford, researchers at Cambridge and the pharmaceutical company Sandoz. See the 2016 interview.

Gohlke was an active participant in the transition to clinical treatment. Reitz’s 2011 personal account describes her contacting Stanford after reading about the animal experiments. It also records her efforts to obtain help while authorization for the proposed treatment remained unresolved. These recollections illuminate patient initiative, although they represent the surgeon’s retrospective perspective rather than an independent account of every administrative decision.

What the early evidence established

The team’s 1982 clinical report described three recipients, making it possible to look beyond the celebrated first operation. Cyclosporin A was the principal immunosuppressive agent, alongside other drugs. The first patient experienced rejection episodes on postoperative days 10 and 25, both successfully treated; normal exercise tolerance was reported ten months after transplantation. A second recipient, treated for Eisenmenger syndrome, had substantially improved eight months after surgery. The third recipient died four days after transplantation with complications affecting several organs.

The report therefore supported cautious optimism, not a claim that combined transplantation had become reliably safe. Its authors attributed the favorable outcomes to experimental preparation, immunosuppression and the advantages of replacing the heart and lungs together. Three cases could demonstrate feasibility and document individual outcomes, but could not establish comparative effectiveness or predict the experience of all future recipients. Reading the successful and fatal outcomes together preserves the uncertainty confronting patients and clinicians at the time.

Recovery, interpretation and legacy

Success also depended on work after the operation. Reitz’s 2011 account describes rehabilitation and nutritional support, discharge after 82 days, and Gohlke’s eventual return home and to work. It also records a limitation in the team’s early understanding: cardiac biopsies were initially treated as a principal means of assessing rejection of the combined graft. Subsequent experience showed that rejection in the heart and lungs could occur separately. The original achievement thus opened a field in which monitoring practices still required revision.

For historical interpretation, the event raises questions about how medical firsts are credited and measured. A named lead surgeon makes a memorable narrative, but the evidence also identifies collaborators, experimental research, drug development and the recipient’s own determination. Recovery and everyday activity offer another measure of achievement alongside operative survival. These are interpretive themes suggested by the documented record, rather than evidence that every participant understood success in the same way.

The lasting significance of 1981 lies in demonstrating that combined replacement could provide sustained benefit while creating new questions about follow-up and graft behavior. The disease terminology, experimental assumptions and treatment descriptions here belong to that historical setting; they should not be read as recommendations for contemporary care.

Sources and further reading